NASDAQ:ACON Aclarion (ACON) Stock Price, News & Analysis → Just Released: Insider's Secret to Trading Options (From Schaeffer’s Research) (Ad) Free ACON Stock Alerts $0.33 +0.04 (+14.58%) (As of 09:34 AM ET) Add Compare Share Share Today's Range$0.29▼$0.3350-Day Range$0.28▼$1.7552-Week Range$0.27▼$25.60Volume674,375 shsAverage Volume1.59 million shsMarket Capitalization$2.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Aclarion alerts: Email Address Ad Schaeffer’s ResearchJust Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.Yes! Show Me This Strategy About Aclarion Stock (NASDAQ:ACON)Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.Read More ACON Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACON Stock News HeadlinesApril 25, 2024 | globenewswire.comAclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back PainApril 23, 2024 | finance.yahoo.comAclarion to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024April 25, 2024 | Schaeffer’s Research (Ad)Just Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.April 16, 2024 | americanbankingnews.comAclarion, Inc. (NASDAQ:ACON) Sees Large Growth in Short InterestApril 2, 2024 | benzinga.comWhy Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionMarch 4, 2024 | finance.yahoo.comAclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar DiscsFebruary 27, 2024 | globenewswire.comAclarion Announces Closing of $3.0 Million Public OfferingFebruary 26, 2024 | msn.comWhy Aclarion (ACON) Shares Are Down Over 60% TodayApril 25, 2024 | Schaeffer’s Research (Ad)Just Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.February 26, 2024 | globenewswire.comAclarion Announces Pricing of $3.0 Million Public OfferingFebruary 26, 2024 | investorplace.comWhy Is Aclarion (ACON) Stock Down 19% Today?February 26, 2024 | investorplace.comWhy Is Aclarion (ACON) Stock Down 19% Today?February 1, 2024 | benzinga.comAclarion Stock (NASDAQ:ACON), Short Interest ReportJanuary 30, 2024 | benzinga.comAclarion Stock (NASDAQ:ACON) Dividends: History, Yield and DatesJanuary 22, 2024 | markets.businessinsider.comEQS-News: Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MDJanuary 22, 2024 | markets.businessinsider.comAclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MDJanuary 3, 2024 | ca.finance.yahoo.comACLARION INC. DL-,00001 (IT2.BE)January 2, 2024 | finance.yahoo.comAclarion Announces Reverse Stock SplitNovember 27, 2023 | finance.yahoo.comAclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan ExamsNovember 9, 2023 | finance.yahoo.comAclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan AdoptionNovember 6, 2023 | markets.businessinsider.comAclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MDOctober 25, 2023 | finance.yahoo.comAclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to DenverOctober 24, 2023 | finance.yahoo.comAclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM MeetingOctober 2, 2023 | finance.yahoo.comAclarion Provides Updated Investor Presentation and Corporate UpdateSeptember 8, 2023 | barrons.comAclarion Inc.August 25, 2023 | finance.yahoo.comAclarion, Inc. Announces Filing of Delayed 10-Q Quarterly ReportJune 14, 2023 | finance.yahoo.comAclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MISee More Headlines Receive ACON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aclarion and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Next Earnings (Estimated)7/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:ACON CUSIPN/A CIK1635077 Webwww.aclarion.com Phone833-275-2266FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,910,000.00 Net Margins-6,480.47% Pretax Margin-6,512.92% Return on Equity-724.93% Return on Assets-249.67% Debt Debt-to-Equity RatioN/A Current Ratio0.40 Quick Ratio0.40 Sales & Book Value Annual Sales$80,000.00 Price / Sales25.74 Cash FlowN/A Price / Cash FlowN/A Book Value($0.38) per share Price / Book-0.76Miscellaneous Outstanding Shares7,150,000Free Float5,559,000Market Cap$2.06 million OptionableNot Optionable Beta0.44 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Jeffrey John Thramann M.D. (Age 59)Executive Chairman Comp: $300kMr. John Lorbiecki (Age 60)Chief Financial Officer Comp: $225kMr. Ryan Bond (Age 51)Chief Strategy Officer Comp: $200kMr. Brent Ness (Age 57)CEO, President & Director Comp: $418.75kKey CompetitorsInvitaeNYSE:NVTAOpGenNASDAQ:OPGNNuwellisNASDAQ:NUWEClearmind MedicineNASDAQ:CMNDQualigen TherapeuticsNASDAQ:QLGNView All Competitors ACON Stock Analysis - Frequently Asked Questions How have ACON shares performed in 2024? Aclarion's stock was trading at $3.20 on January 1st, 2024. Since then, ACON shares have decreased by 91.0% and is now trading at $0.2880. View the best growth stocks for 2024 here. Are investors shorting Aclarion? Aclarion saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 62,000 shares, an increase of 9.3% from the March 15th total of 56,700 shares. Based on an average daily volume of 1,890,000 shares, the short-interest ratio is currently 0.0 days. Approximately 1.0% of the company's stock are short sold. View Aclarion's Short Interest. When is Aclarion's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 1st 2024. View our ACON earnings forecast. When did Aclarion's stock split? Aclarion shares reverse split on the morning of Thursday, January 4th 2024. The 1-16 reverse split was announced on Thursday, January 4th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did Aclarion IPO? Aclarion (ACON) raised $12 million in an IPO on Friday, April 22nd 2022. The company issued 2,165,000 shares at $4.50-$6.50 per share. How do I buy shares of Aclarion? Shares of ACON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACON) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry ResearchNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclarion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
